Abstract: Heart failure (HF) represents the most common endpoint of most cardiovascular diseases (CVDs) which are the leading causes of death around the world. Despite the advances in treating CVDs, the prevalence of HF continues to increase. It is believed that better results of prognosis are obtained from prevention rather than additional treatment for HF. Therefore, it is reasonable to prevent the development of CVDs or other complications to HF. Most types of HF are attributed to contractile dysfunction, cardiac hypertrophy or remodeling, and ischemic injuries. SIRT3 is a mitochondrial nicotinamide adenine dinucleotide (NAD + )-dependent deacetylase whose substrates vary from metabolic biogenesis-associated proteins to stress-responsive proteins. In recent years, a number of studies have highlighted the cardio-protective role of SIRT3 and, as such, efforts have been made to induce over-expression or increased activity of this protein. In this review, we provide an overview of the roles of SIRT3 in cardiac hypertrophy induced by pressure overload or agonists and cardiomyocytes ischemic injuries. Moreover, we will introduce the application of SIRT3 agonists in the prevention of cardiac hypertrophy and ischemia reperfusion injury.
Introduction
Cardiovascular diseases (CVDs), which include hypertension, coronary heart diseases, valvular heart diseases, etc., are the most common causes of death around the word. According to the American Heart Association, CVDs have led to 32% of the deaths in United States since 1900, which is greater than cancer and chronic lower respiratory disease (CLRD) combined (Mozaffarian et al., 2016) . Similar trends are observed in Europe, where CVDs are also the leading causes of death, and are responsible for half of all deaths each year (Townsend et al., 2015) . As a result, heart failure (HF) is the common endpoint for most CVDs (Lüscher, 2015) . Therapeutic strategies for HF emphasize normalization of hemodynamics and suppression of neurohumoral activation, which include pharmacological approaches, cardiac resynchronization therapy (CRT), certain disease management, and educational approaches (Yancy et al., 2013) , but only CRT and certain disease management could improve the health-related quality of life (HRQOL) in HF (Schwer and Verdin, 2008; Lorenzen et al., 2012; Kober, 2016) . However, it is believed that the prognosis can best be improved by prevention versus treatment for HF (Kober, 2016) . Therefore, it is necessary to further characterize the mechanisms of pathogenesis and progression of HF to achieve additional benefits for patients.
Epigenetic modification has been demonstrated to play an important role in CVD (Lorenzen et al., 2012) . Histone acetylation is an epigenetic modification, Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology) ISSN 1673-1581 (Print); ISSN 1862-1783 (Online) www.zju.edu.cn/jzus; www.springerlink.com E-mail: jzus@zju.edu.cn which is evolutionarily conserved from prokaryotes to eukaryotes (Schwer and Verdin, 2008; Finkel et al., 2009) . This covalent modification is mediated by histone acetyltransferases such as Gcn5/PCAF (general control nonderepressible-5/p300/cyclic adenosine monophosphate (cAMP)-response element binding protein binding protein (CBP)-associated factor) family and p300/CBP family, which can also acetylate non-histone proteins (Eckner, 1996; Lerin et al., 2006) . Mammalian deacetylases are classified into four groups according to their phylogenic and sequence homology. Classes I, II, and IV deacetylases function as histone deacetylases and use zinc as a cofactor (Yang and Seto, 2007) . Class III deacetylases, also defined as sirtuins, are NAD + -dependent enzymes. Accordingly, the dependency of their activity on NAD + indicates the links of sirtuins and energy or redox status. Sirtuins consist of seven members and play extensive roles in CVDs (Winnik et al., 2015) . Notably, SIRT3 is the only sirtuin family member linked to longevity of human life (Rose et al., 2003; Bellizzi et al., 2005) . The expression of SIRT3 is down-regulated in individuals over 60 years of age when compared to younger individuals, while endurance exercise leads to up-regulation of SIRT3 along with an improved health condition (Lanza et al., 2008) . Given that CVD presents the most common pathology in individuals older than 60 years, these results suggest that SIRT3 may play an important cardioprotection role. In this review we will discuss the roles of SIRT3 in HF-associated complications and its prospective treatment implication.
Epidemiology and pathophysiology of HF
In the United States, more than 5 million individuals manifest HF with 870 000 new cases diagnosed annually. Notably, the prevalence of HF continues to rise despite advancements in the prevention, diagnosis and treatment of CVDs (Mozaffarian et al., 2016) . Hospital discharges of patients with a primary diagnosis of HF have continuously risen since 1975, and now represent more than 1 million patients discharged each year (Chen et al., 2011) . In Europe, HF affects nearly 10% of men and 8% of women over the age of 60 years, with a prevalence that increases with age (Townsend et al., 2015) . Two hypotheses have been proposed to explain this phenomenon. On one hand, disorders that lead to HF are not cured although the treatments of them have advanced, which leads to an increased number of patients living with HF. On the other hand, there is a large elderly population with various cardiovascular complications due to aging populations. Except for the CVDs, there are more and more age-associated chronic comorbid conditions with adverse cardiac consequences, which include type 2 diabetes mellitus, chronic obstructive pulmonary diseases, and chronic renal disease (Al-Ahmad et al., 2001; Kamalesh, 2007; Hannink et al., 2010) . Therefore, it is reasonable to focus on the prevention and treatment of disorders responsible for HF.
In recent decades, considerable attention has been placed on elucidating the pathogenesis and progression of HF in a variety of models. The mechanisms are complex and proved to be interacted. Spann et al. (1967) investigated the intrinsic contractility of cardiac muscle in a cat HF model induced by pressure overload, and discovered a reduction in the force development of cardiac muscle isolated from the HF cats. This is the earliest study supporting the hemodynamic model, which lays the foundation for the pathophysiology of HF. In this hemodynamic model, it is believed that the heart fails to pump enough blood for the requirements of tissues during ordinary activity in the state of pathology induced by hemodynamic overload. Accompanied with hemodynamic overload is cardiac remodeling, which has been viewed as a characteristic pathological change during HF, caused by cell death, proliferation or hypertrophy of various cell types, and reconstruction of the extracellular matrix. In patients with HF with preserved ejection fraction (HFPEF), the left ventricular volume is normal but the wall is thickened and the myocardial stiffness is increased (Ohtani et al., 2012) . However, in patients with HF with reduced ejection fraction (HFREF), the left ventricular is dilated and its thickness is either normal or reduced (Borbely et al., 2005) . Notably, it has been demonstrated that the deletion of cardiomyocytes ultimately leads to HF (Olivetti et al., 1997) . Nearly all types of HF are accompanied by increased cell death, attributed to stresses from circulating neurohormones, inflammation, oxidative stress, or toxins (Konstantinidis et al., 2012; Richter and Kostin, 2015) . This leads to the release of growth factors which can result in the formation of fibrosis (Gandhi et al., 2011) . In conjunction with cell death, remodeling of the extracellular matrix is also observed. Either inadequate fibrosis, which leads to thinning of the ventricular wall or increased synthesis of extracellular matrix, which enhances the ventricular stiffness, is believed to weaken their pumping function and contributes to HF (Katz and Zile, 2006) . Another factor contributed to cardiac remodeling is inflammation. Immune activation and inflammation response occur in patients with HF and act as a double-edged sword. On one hand, it is an adaptive and reparative response to heart injury through scavenging the detrimental subjects and rebuilding the microenvironment by recruiting the inflammatory cells and secreting cytokines. On the other hand, overactivation of inflammation not only leads to the death or hypertrophy of cells comprising the heart tissue, but also results in excessive fibrosis (Briasoulis et al., 2016) . The neurohumoral model of HF has drawn great attention from researchers in recent years, which causes effects on HF in many aspects. In the compensated period, the activation of the adrenergic nervous system and reninangiotensin-aldosterone system contributes to the increase of heart contractility and redistribution of blood. However, in the decompensated period, they lead to depressed contractility of the failing heart and increased blood pressure by causing maladaptive remodeling of the ventricular and vascular (Braunwald, 2013) . More recently, cardiac genetic research has identified several important monogenic disorders or gene mutations of inherited cardiomyopathies that lead to HF (Morita et al., 2005; Herman et al., 2012; Towbin, 2014) . In addition, the current investigations focused on searching for disease-associated genetic variants by scanning the entire genome using genome-wide-association-studies (Zeller et al., 2012) . Despite these advances, our understanding of the pathogenesis of HF remains incomplete.
Characteristics and functions of SIRT3
To identify the biological function of a gene, it is necessary to resolve the protein structure and subcellular localization. Human SIRT3 protein includes a full length (44 kD) and short length (28 kD) form, which lacks the N-terminal 142 residues. Onyango et al. (2002) have analyzed the protein structure of full length SIRT3 using the bioinformatic methods, identifying six motifs within the protein. Two of these motifs were HTHLACI1 and PNDRDTASEI6, indicating that SIRT3 may possess enzymatic activities. Another two motifs were matched to GLUTRNSPORT, a glucose transporter signature. Other matches included a zinc finger motif, suggesting the potential interaction between SIRT3 and DNA, and protein or itself. They also observed that the expression of SIRT3 in metabolically active tissues such as liver, muscle, heart, and kidney was significantly elevated, indicating that SIRT3 may participate in metabolic homeostasis. They also identified that the N-terminus containing a mitochondrial localization signal was necessary for its localization. However, a controversial report argued that endogenous SIRT3 is located in the nucleus and translocates into mitochondria under cellular stress or following over-expression of SIRT3 (Scher et al., 2007) . In the study of Sundaresan et al. (2008) , full length SIRT3 localized to the mitochondria, nucleus, and cytoplasm, while the short form localized exclusively to the mitochondria of the mouse cardiomyocytes. These results were confirmed by recent studies (Chen et al., 2015b) . The discrepancy is believed to be due to differences in cell types used between the studies and the stages of cell life when SIRT3 was detected.
SIRT3 is a soluble mitochondrial protein highly expressed in mitochondrial rich tissues and also plays critical roles related to tumor suppression, cellular stress, fat acid metabolism, oxidative stress response, and age-associated hearing loss (Hirschey et al., 2010; Kim et al., 2010; Someya et al., 2010) . Lombard et al. (2007) found that no abnormalities were identified in SIRT3-deficient mice under non-stress conditions; however, the hyperacetylation of mitochondrial proteins was observed when stress was applied. Using a comprehensive multi-tissue quantitative acetylproteome analysis approach, Dittenhafer-Reed et al. (2015) identified 6286 acetylation sites, of which nearly 4000 were localized to mitochondrial proteins. They also conducted a biological pathway analysis to assess pathways regulated by SIRT3-mediated acetylation, revealing that fuel-producing and fuelutilizing tissues display unique SIRT3-dependent alterations and that SIRT3 is coupled to metabolic homeostasis. Despite these studies, most of the functions of SIRT3 remain to be investigated.
Role of SIRT3 in ameliorating cardiac hypertrophy
Cardiac hypertrophy is an adaptive response to increased mechanical stress from physiological or pathological stimuli. Both intrinsic factors such as hypertrophic cardiomyopathy or ischemia-induced remodeling and extrinsic factors such as increased volume or pressure overload contribute to hypertrophy. In the period of compensated hypertrophy, there is no significant impact on the cardiac performance, but decompensated hypertrophy results in contractile dysfunction and HF.
The heart is the greatest oxygen consuming organ, needing a persistent supply of energy to drive circulation. Moreover, nearly all cellular processes of cardiomyocytes are driven by ATP-dependent pathways. As an energy producing organelle, the mitochondria encompasses about 1/3 of the cellular volume in cardiomyocytes (Schaper et al., 1985) . Mitochondrial fatty acid and glucose oxidation represent the major sources of ATP generation in healthy hearts (Bing et al., 1954; Taegtmeyer, 1994; Stanley and Chandler, 2002) . Although increased mitochondrial respiratory activity is observed during the early stages of cardiac hypertrophy, the oxidative phosphorylation rate decreases upon progression to decompensated hypertrophy or HF (Lindenmayer et al., 1971; Sordahl et al., 1973) . Mitochondrial SIRT3 is reported to play important roles in maintaining basal ATP levels and regulating energy production. Ahn et al. (2008) demonstrated a >50% decline of basal ATP levels with concomitant hyperacetylation of mitochondrial proteins in SIRT3 −/− mice, while reconstitution with wild-type SIRT3 restored ATP levels in mouse embryonic fibrioblasts. Smith et al. (2011) further analyzed the deacetylation activity of SIRT3 using peptide arrays and machine learning. They confirmed a variety of potential SIRT3 substrates which participate in ATP synthesis, fatty acid oxidation, and the urea cycle. In the recent studies from Chen et al. (2015b) and Koentges et al. (2015) , SIRT3 is reported to attenuate cardiac hypertrophy and dysfunction induced by transverse aortic constriction (TAC) by regulating the acetylation of mitochondrial proteins. Chen et al. (2015b) demonstrated that the short form of SIRT3 was downregulated in the hypertrophic heart accompanied by higher levels of acetylation of long-chain acetyl-CoA dehydrogenase (LCAD) which participates in fatty acid oxidation. Moreover, SIRT3-KO mice exhibited severer hypertrophy and increased accumulation of lipids. Upon SIRT3 over-expression in cardiomyocytes, lipid accumulation was attenuated through the deacetylation of LCAD. In support of these findings, Koentges et al. (2015) identified a decrease of cardiac function in the working heart isolated from SIRT3-KO mice. Oxidation of palmitate and glucose was decreased, while the rates of glycolysis increased. In addition, they identified hyperacetylation of 84 mitochondrial proteins including enzymes related to fatty acid transport and oxidation, subunits of the electron transport chain and enzymes involved in the tricarboxylic acid cycle. In Angiotension II-induced cardiac hypertrophy, the protective effect of SIRT3 was also observed through increasing the NAD level by interacting and deacetylating nicotinamide mononucleotide adenylyltransferase 3 (NMNAT3), the rate-limiting enzyme for mitochondrial NAD biosynthesis (Yue et al., 2016) . These results suggest that SIRT3 participates in the mitochondrial metabolism and energy production of the heart, which is associated with the maintenance of the cardiac function.
Reactive oxygen species (ROS) are normal mitochondrial metabolic products involved in energy production, which have been shown to contribute to the development of cardiac hypertrophy (Cole et al., 2006 , van Empel et al., 2006 . A variety of hypertrophic pathways activated by ROS have been identified, including mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase 1/2 (ERK1/2), protein kinase C (PKC), c-Jun N-terminal kinase (JNK), phosphoinositide-3 kinase (PI3K), protein kinase B (PKB), and nuclear factor-κB (NF-κB) Wenzel et al., 2007; Adiga and Nair, 2008; Zhang et al., 2008; Zou et al., 2008; Cai et al., 2009; Guo et al., 2009) . Interestingly, inhibition of ROS by antioxidants is believed to block cardiac hypertrophy induced by angiotensin II (Hu et al., 2006) . There are two cellular mechanisms used to counteract ROS, which include: (1) antioxidant enzymes such as superoxide dismutase (SOD), catalase, and peroxidases, and (2) reductant species such as glutathione and thioredoxin (Berndt et al., 2007) . Manganese SOD and catalase are enhanced by the forkhead transcription factor box O family (FoxOs) (Daitoku et al., 2004; Tan et al., 2008) which could be regulated by SIRT3 deacetylase activity (Tseng et al., 2013) . Intriguingly, SIRT3 has been proven to ameliorate the cardiac hypertrophy by eliminating ROS through deacetylation and activating FoxO3a (Sundaresan et al., 2009) .
In addition to the mechanisms mentioned above, several disputable or potential explanations have also been suggested in recent years. Zeng et al. (2015) found that mice fed with high-fat-diet (HFD) showed cardiac hypertrophy and dysfunction with reduced capillary density, increased ROS production, and impaired HIF signaling. In this context, SIRT3 was down-regulated by HFD. SIRT3-KO mice showed similar but more severe phenotypes with HFD mice, while the capillary density in the SIRT3-KO mice was not further reduced by HFD. These results indicate that SIRT3 may play an important role in preserving cardiac function and capillary density in the HFDinduced obesity, but the mechanisms involved remain to be further clarified. In another study, Hafner et al. (2010) found that SIRT3 deficient mice showed cardiac hypertrophy and fibrosis accompanied by increased opening of the mitochondrial permeability transition pore (mPTP) and mitochondrial swelling at 13 months of age. They also observed that SIRT3 could deacetylate cyclophilin D, a component of mPTP, on lysine 166, which led to inhibition of the mPTP opening. From these data, they suggested that SIRT3 could prevent age-related mitochondrial dysfunction and cardiac hypertrophy.
Role of SIRT3 in attenuating ischemia and/or reperfusion-induced injury
Ischemic heart disease, which is triggered by temporary or permanent blockage of the coronary blood flow, can result in heart disability or even sudden death. Furthermore, most patients with myocardial infarction (MI) will develop into HF. Despite the advancement in therapy for MI, chronic HF induced by MI remains the chief cause of mortality (Velagaleti et al., 2008; Hung et al., 2013; Greco et al., 2015) . Thus, improving the therapeutic effect for MI or preventing the progression to HF remains a critical concern. Early reperfusion is believed to be the most effective therapy to reduce myocardial damage induced by ischemia and hypoxia (Zhang and Huo, 2011) , but the benefits of blood restoration are soon attenuated by reperfusion injury (Piper et al., 1998) . Although some strategies, such as postconditioning, have been put forward to ameliorate the reperfusion injury, the incidences of total major cardiac events were not decreased (Hu et al., 2014) . Several mechanisms have been discovered, including calcium overload, increased ROS formation, autophagy, apoptosis, and mitochondrial dysfunction (Murphy and Steenbergen, 2008; Marzetti et al., 2013) . Intriguingly, these mechanisms interacted with each other. As such, it is a challenge to achieve and overcome the negative complications associated with the management of ischemia reperfusion.
Fortunately, SIRT3 has been demonstrated to participate in numerous biological processes including anti-oxidation reactions, cell survival, and mitochondrial protection, all of which could contribute to the treatment of ischemic heart disease (Kim et al., 2010; Someya et al., 2010; Dittenhafer-Reed et al., 2015) . Since loss of cardiomyocytes due to cell death is the main cause of cardiac dysfunction following MI, inhibition of apoptosis or necrosis is a critical necessity. It has been shown that SIRT3 is able to protect cardiomyocytes from apoptosis induced by genotoxic and oxidative stress through an extra-mitochondrial pathway by deacetylating Ku-70 (Sundaresan et al., 2008) . Sundaresan et al. (2008) examined the cell survival by subjecting cardiomyocytes to the stress of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) or H 2 O 2 . They observed a reduction of apoptosis mediated by Bax which is hindered by Ku-70 binding, and confirmed that increased binding of Bax and Ku-70 is due to the deacetylation of Ku-70 by SIRT3. Chen et al. (2013) pointed out that NF-κB represents another target of SIRT3, which is responsible for the survival of cardiomyocytes exposed to H 2 O 2 . They found that SIRT3 was down-regulated by oxidative stress in H9C2 cardiomyocytes and treatment with resveratrol reversed the stress-induced expression changes. Over-expression of SIRT3 induces NF-κB to exit the nucleus and alter the expression of apoptosis-related genes, Bcl-2 and Bax. As mentioned above, SIRT3 is able to deacetylate the mPTP component CyPD and inhibit its opening. Bochaton et al. (2015) confirmed that SIRT3 was also necessary for the prevention of reperfusion injury via a mechanism which is similar to that observed with the inhibition of mPTP opening by CyPD. Thus, while SIRT3 plays an important role in protecting cardiomyocytes from oxidative or ischemia reperfusion injury in vitro, it remains to be determined if the same effects can be seen in vivo.
Application perspectives
As a member of sirtuins, SIRT3 functions as a deacetylase that takes part in various cellular processes, including cell growth and survival, apoptosis, senescence, metabolism, and mitochondrial integrity. Even though the deacetylase activity of SIRT3 has been confirmed and thousands of substrates have been detected using multi-tissue quantitative proteomics, bioinformatic analysis, and biochemical validation (Schaper et al., 1985; Taegtmeyer, 1994) , few functions have been performed, particularly as they relate to heart diseases. In this context, we have discussed the protective roles of SIRT3 in cardiac hypertrophy and ischemia reperfusion or oxidative stress-induced cell death which are the chief causes of HF. Otherwise, there remains a quantity of questions to be answered regarding the cardioprotective role of SIRT3, considering that most substrates localized in mitochondria are required to be investigated (Verdejo et al., 2012) . For instance, SIRT3 has been demonstrated to activate peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α), which takes part in mitochondrial biogenesis, but the role of SIRT3 in mitochondrial biogenesis and its association with cardiac hypertrophy remain to be clarified. Moreover, the effects of SIRT3 on HF induced by metabolic disorders such as type 2 diabetes also need to be investigated for its regulatory function in metabolism.
Recently, several pharmacological agents have been discovered that can lead to activation of SIRT3 and cardioprotection. Resveratrol is the first compound to be demonstrated to activate sirtuins and it is broadly investigated in CVD as a SIRT1 agonist; however, there have been few publications regarding its role in activating SIRT3. Chen et al. (2015a) recently confirmed that resveratrol could activate SIRT3, then prevent cardiac hypertrophy, and ameliorate the cardiac fibrosis through inhibiting the transforming growth factor (TGF)-β/Smad3 pathway.
The mechanisms are proved to be that activation of SIRT3 by resveratrol down-regulates TGF-β and brings about dephosphorylation of the Smad3, which leads to the down-regulation of plasminogen activator inhibitor-1 (PAI-1) and decreased activities of plasmin-dependent matrix metalloproteinases. In addition, Pillai et al. (2015) have identified the protective effects of Honokiol and demonstrated this agent prevented cardiac hypertrophic responses and attenuated pre-existing cardiac hypertrophy via SIRT3 activation. Losartan is an angiotensin II type I receptor blocker that was introduced as an antihypotension medicine. Klishadi et al. (2015) demonstrated that it exerted protective effects in ischemia reperfusion injuries by normalizing the protein level of SIRT3 and up-regulating the pro-survival factors in ischemic heart. Recently, another molecular Adjudin, which was developed as an anti-spermatogenic agent, was proved to directly activate mitochondrial-located SIRT3 in hair cells of the cochlea (Xia and Geng, 2016) . Its role in cardiac cells was expected. Therefore, the pharmacological intervention for SIRT3 activity has emerged, which sheds light on its clinical applications.
In conclusion, SIRT3 exerts various benefits in cardiac hypertrophy and ischemic heart disease, and may represent a novel therapeutic target of addressing HF in the near future.
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